Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05131438
Title An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
Recruitment No longer available
Gender both
Phase Expanded access
Variant Requirements No
Sponsors EQRx International, Inc.
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.